专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090304755A1 PHARMACEUTICAL FORMULATION OF LOSARTAN 审中-公开
标题翻译：洛萨坦的药物制剂
公开(公告)号：US20090304755A1
公开(公告)日：2009-12-10
申请号：US12091852
申请日：2006-01-06
申请人： Raghu Rami Reddy Kasu , Dhanashree Mistry , Sunderraj Manvi , Vijaya Kumar Thommandru , Himadri Sen
发明人： Raghu Rami Reddy Kasu , Dhanashree Mistry , Sunderraj Manvi , Vijaya Kumar Thommandru , Himadri Sen
IPC分类号： A61K9/00 , A61K31/5415 , A61P9/12
CPC分类号： A61K9/2077 , A61K9/2866 , A61K31/4178 , A61K31/54 , C07D403/10 , A61K2300/00
摘要： A pharmaceutical composition comprising losartan and pharmaceutically acceptable salts thereof and a process of forming the same. The pharmaceutical composition of losartan comprises an active agent comprising an effective amount of losartan or its pharmaceutical salt thereof, and pharmaceutically acceptable additives, wherein d(0.9) of losartan is less than 50μ and/or specific surface area is more than 0.6 m2/gm. The process of preparation of pharmaceutical composition of losartan, comprises the steps of blending the losartan having d(0.9) less than 50μ and/or specific surface area more than 0.6 m2/gm, with the other intragranular excipients, dry compression, milling and screening to obtain granules, said granules being subsequently blended with extragranular excipients and compressed to tablets which is further coated.
摘要翻译：包含氯沙坦及其药学上可接受的盐的药物组合物及其形成方法。氯沙坦的药物组合物包含有效量的氯沙坦或其药用盐和药学上可接受的添加剂的活性剂，其中d（0.9）的氯沙坦小于50mu，和/或比表面积大于0.6m 2 / gm 。制备氯沙坦药物组合物的方法包括将d（0.9）小于50mu和/或比表面积大于0.6m 2 / gm的氯沙坦与其它颗粒内赋形剂，干压缩，研磨和筛选为了获得颗粒，所述颗粒随后与颗粒外赋形剂混合并压制成进一步包被的片剂。

2. 发明申请

US20130039957A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BRIVARACETAM 审中-公开
标题翻译：控制释放BRIVARACETAM的药物组合物
公开(公告)号：US20130039957A1
公开(公告)日：2013-02-14
申请号：US13643922
申请日：2011-04-26
申请人： Raghu Rami Reddy Kasu , Subhasis Das , Vijaya Kumar Thommandru
发明人： Raghu Rami Reddy Kasu , Subhasis Das , Vijaya Kumar Thommandru
IPC分类号： A61K9/00 , A61P25/08 , A61K31/4015
CPC分类号： A61K31/4015 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2068 , A61K9/2077 , A61K9/2853 , A61K9/2866
摘要： The present invention relates to controlled release pharmaceutical compositions comprising Brivaracetam or its pharmaceutically acceptable derivatives thereof. Further disclosed is a controlled release pharmaceutical composition comprising a core and a coating surrounding the core, wherein the core comprises Brivaracetam or pharmaceutically acceptable derivative thereof and the coating comprises hydrophobic release controlling agent. The controlled release pharmaceutical composition comprises Brivaracetam or pharmaceutically acceptable derivatives thereof and hydrophobic release controlling agent, wherein said composition has dissolution of Brivaracetam at least 80% between about 7 to about 24 hours when measured in 900 ml of pH 6 phosphate buffer solution using USP apparatus type II, at 50 rpm and at 37° C. Also disclosed is a controlled release pharmaceutical composition useful for the treatment of epilepsy and treatment of symptomatic myoclonus comprises Brivaracetam or pharmaceutically acceptable derivative thereof and hydrophobic release controlling agent.
摘要翻译：本发明涉及包含布立西坦或其药学上可接受的衍生物的控释药物组合物。进一步公开了一种控释药物组合物，其包含核心和包围核心的包衣，其中所述核心包含布立西坦或其药学上可接受的衍生物，并且所述包衣包含疏水释放控制剂。控释药物组合物包含布立西坦或其药学上可接受的衍生物和疏水释放控制剂，其中当使用USP装置在900ml pH6磷酸盐缓冲溶液中测量时，所述组合物在约7至约24小时之间溶解至少80％的布立西坦 II型，50rpm和37℃。还公开了可用于治疗癫痫的治疗药物组合物和治疗症状性肌阵挛的治疗药物，其包含布立西坦或其药学上可接受的衍生物和疏水性释放控制剂。

3. 发明授权

US10130624B2 Pharmaceutical compositions of amlodipine and benazepril 有权
公开(公告)号：US10130624B2
公开(公告)日：2018-11-20
申请号：US11886354
申请日：2006-01-25
申请人： Veena Vithalapuram , Vijaya Kumar Thommandru , Himadri Sen
发明人： Veena Vithalapuram , Vijaya Kumar Thommandru , Himadri Sen
IPC分类号： A61K31/455 , A61K31/55 , A61K9/48 , A61K9/50
摘要： A stable pharmaceutical composition consisting of (a) benazepril, in free or pharmaceutically acceptable salt form; and (b) amlodipine, in free or pharmaceutically acceptable salt form. The composition is free of alkali and alkaline earth metal carbonates and phosphates. The composition is also free of excipients which increase the pH of microenvironment above 5. It is therefore not required to physically separate the two drugs from each other.

4. 发明申请

US20080194542A1 Pharmaceutical Compositions of Amlodipine and Benazepril 审中-公开
标题翻译：氨氯地平和贝那普利的药物组合物
公开(公告)号：US20080194542A1
公开(公告)日：2008-08-14
申请号：US11886354
申请日：2006-01-25
申请人： Veena Vithalapuram , Vijaya Kumar Thommandru , Himadri Sen
发明人： Veena Vithalapuram , Vijaya Kumar Thommandru , Himadri Sen
IPC分类号： A61K31/55
CPC分类号： A61K31/455 , A61K9/4808 , A61K9/4858 , A61K9/5084 , A61K31/55 , A61K2300/00
摘要： A stable pharmaceutical composition consisting of (a) benazepril, in free or pharmaceutically acceptable salt form; and (b) amlodipine, in free or pharmaceutically acceptable salt form. The composition is free of alkali and alkaline earth metal carbonates and phosphates. The composition is also free of excipients which increase the pH of microenvironment above 5. It is therefore not required to physically separate the two drugs from each other.
摘要翻译：由（a）贝那普利，游离或药学上可接受的盐形式组成的稳定的药物组合物; 和（b）氨氯地平，游离或药学上可接受的盐形式。该组合物不含碱金属和碱土金属的碳酸盐和磷酸盐。该组合物也不含增加微环境高于5的pH值的赋形剂。因此不需要将这两种药物彼此物理分离。

5. 发明申请

US20120077817A1 NOVEL PHARMACEUTICAL COMPOSITIONS OF RANOLAZINE 有权
标题翻译： RANOLAZINE的新型药物组合物
公开(公告)号：US20120077817A1
公开(公告)日：2012-03-29
申请号：US13322846
申请日：2010-05-26
申请人： Ketan Bhasale , Raghavendra Naik , Subhasis Das , Vijaya Kumar Thommandru
发明人： Ketan Bhasale , Raghavendra Naik , Subhasis Das , Vijaya Kumar Thommandru
IPC分类号： A61K31/495 , A61P9/10
CPC分类号： A61K9/2013 , A61K9/2077 , A61K31/495
摘要： A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more lipid(s) as release controlling agent(s) and one or more pharmaceutically acceptable excipient(s).
摘要翻译：一种新颖的控释药物剂型，其包含治疗有效量的雷洛嗪或其药学上可接受的盐，多晶型物，溶剂合物，水合物，对映异构体，一种或多种脂质，作为释放控制剂和一种或多种药学上可接受的赋形剂。

6. 发明授权

US08901128B2 Pharmaceutical compositions of ranolazine 有权
标题翻译：雷诺嗪的药物组合物
公开(公告)号：US08901128B2
公开(公告)日：2014-12-02
申请号：US13322846
申请日：2010-05-26
申请人： Ketan Bhasale , Raghavendra Naik , Subhasis Das , Vijaya Kumar Thommandru
发明人： Ketan Bhasale , Raghavendra Naik , Subhasis Das , Vijaya Kumar Thommandru
IPC分类号： A61K31/495 , A61K9/22 , A61K9/20
CPC分类号： A61K9/2013 , A61K9/2077 , A61K31/495
摘要： A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more lipid(s) as release controlling agent(s) and one or more pharmaceutically acceptable excipient(s).
摘要翻译：一种新颖的控释药物剂型，其包含治疗有效量的雷洛嗪或其药学上可接受的盐，多晶型物，溶剂合物，水合物，对映异构体，一种或多种脂质，作为释放控制剂和一种或多种药学上可接受的赋形剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式